Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 191

Similar articles for PubMed (Select 16774493)

1.

Incidence and management of bevacizumab-related toxicities in colorectal cancer.

Saif MW, Mehra R.

Expert Opin Drug Saf. 2006 Jul;5(4):553-66. Review.

PMID:
16774493
2.

Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.

Tappenden P, Jones R, Paisley S, Carroll C.

Health Technol Assess. 2007 Mar;11(12):1-128, iii-iv. Review.

3.
4.

Integration of novel agents in the treatment of colorectal cancer.

Iqbal S, Lenz HJ.

Cancer Chemother Pharmacol. 2004 Sep;54 Suppl 1:S32-9. Review.

PMID:
15309512
5.

Bevacizumab in the treatment of colorectal cancer.

Mulcahy MF, Benson AB 3rd.

Expert Opin Biol Ther. 2005 Jul;5(7):997-1005. Review.

PMID:
16018743
6.

Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.

Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, Hambleton J, Novotny WF, Kabbinavar F.

J Clin Oncol. 2005 May 20;23(15):3502-8.

7.

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.

Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R, Perrou B, Nelson B, Novotny WF.

J Clin Oncol. 2005 Jun 1;23(16):3697-705. Epub 2005 Feb 28.

8.

Can inhibition of angiogenic pathways increase the efficacy of intravenous 5-fluorouracil-based regimens?

Kabbinavar FF, Ellis LM.

Clin Colorectal Cancer. 2004 Oct;4 Suppl 2:S69-73. Review.

PMID:
15479482
9.

Safety and tolerability of first-line bevacizumab in metastatic colorectal cancer.

Akun E, Okutur K, Seber S, Korkmaz T, Aydin K, Bozkurt M, Namal E, Hasbal B, Tecimer C, Demir G.

J BUON. 2012 Oct-Dec;17(4):669-76.

PMID:
23335523
10.

Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis.

Kang BW, Kim TW, Lee JL, Ryu MH, Chang HM, Yu CS, Kim JC, Kim JH, Kang YK, Lee JS.

Med Oncol. 2009;26(1):32-7. doi: 10.1007/s12032-008-9077-8. Epub 2008 May 22.

PMID:
18498064
11.
12.

Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events.

Hurwitz H, Saini S.

Semin Oncol. 2006 Oct;33(5 Suppl 10):S26-34. Review.

PMID:
17145522
13.

Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.

Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S.

J Clin Oncol. 2005 Jun 1;23(16):3706-12. Epub 2005 May 2.

14.

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.

Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E.

J Clin Oncol. 2003 Jan 1;21(1):60-5.

PMID:
12506171
15.

The role of bevacizumab as first-line therapy for colon cancer.

Marshall J.

Semin Oncol. 2005 Dec;32(6 Suppl 9):S43-7. Review.

PMID:
16399431
17.

Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.

Shih T, Lindley C.

Clin Ther. 2006 Nov;28(11):1779-802. Review.

PMID:
17212999
18.

Intricacies of bevacizumab-induced toxicities and their management.

Gressett SM, Shah SR.

Ann Pharmacother. 2009 Mar;43(3):490-501. doi: 10.1345/aph.1L426. Epub 2009 Mar 3. Review.

PMID:
19261963
19.

Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer.

Hurwitz H, Kabbinavar F.

Oncology. 2005;69 Suppl 3:17-24. Epub 2005 Nov 21. Review.

PMID:
16301832
20.

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.

Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M, Mazier MA, Canon JL, Georgoulias V, Peeters M, Bridgewater J, Cunningham D; First BEAT investigators.

Ann Oncol. 2009 Nov;20(11):1842-7. doi: 10.1093/annonc/mdp233. Epub 2009 Apr 30.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk